The global sepsis diagnostics market size is expected to reach USD 771 million by 2026 from USD 503 million in 2021, at a CAGR of 8.9%. The growth of this market is primarily driven by the rising prevalence of sepsis across the globe, the growing geriatric population, the increasing number of surgical procedures, and a high incidence of HAIs that are driving the growth of the sepsis diagnostics market. These factors have prompted market players to improve and strengthen their current manufacturing and distribution capabilities—especially in emerging markets, which are expected to witness the highest growth.
Some of the prominent players operating in the global sepsis diagnostics market include bioMérieux (France), Becton, Dickinson and Company (US), Danaher Corporation (US), T2 Biosystems (US), Luminex (US), Roche Diagnostics (Switzerland), Thermo Fisher Scientific (US), Bruker Corporation (US), Abbott Laboratories (US), Immunexpress (Australia), Axis-Shield Diagnostics (UK), Quidel Corporation (US), Siemens Healthineers (Germany), EKF Diagnostics (UK), Seegene Inc., (South Korea), Boditech Med (South Korea), Alifax S.r.l. (Italy), AdvanDx (US), (US), Immunexpress (Australia), and Axis-Shield Diagnostics (UK).
To know about the assumptions considered for the study download the pdf brochure
bioMérieux is one of the leading players in the global sepsis diagnostics market. Its growth strategies include significant investments in R&D activities, product approvals, and expanding geographic reach worldwide. The company has received FDA and CE approvals for many products, which has helped it expand its molecular diagnostics and infectious disease testing product portfolio in the market. With a strong geographical presence and robust product portfolio, the company is expected to witness high growth in the sepsis diagnostics market in the coming years.
The company operates in more than 160 countries across North America, Europe, Oceania, Africa, and the Asia Pacific. It has 18 production sites and 20 R&D centers located across the globe, including the US, Brazil, China, Australia, Canada, France, and Spain.
Becton Dickinson And Company (US)
BD commands a significant share in the global sepsis diagnostics market. Intending to improve a patient’s quality of life, the company concentrates on developing new products and focusing its efforts on gaining product approvals. Its large share is attributed to its robust portfolio, including automated blood culture instruments, blood culture medium, blood culture consumables, and laboratory data management software.
In addition, the company has an extensive distribution network in both developed and developing nations for the supply of its medical products. As a significant amount of the company’s sales is dependent on its operations outside the US, the company anticipates future growth in sales to also come mainly from regions besides the US. Thus, to expand its solutions through innovation and product approvals, the company is expected to grow rapidly in the coming years.
Sepsis Diagnostics Market by Technology (Microbiology, PCR, Sequencing, Biomarkers), Product (Reagents, Assay, Instruments, Software), Test Type (Lab, POC), Pathogen (Bacterial, Viral, Fungal), End User (Hospital, Pathology Lab) - Global Forecast to 2026
Mr. Aashish Mehra
630 Dundee Road
Northbrook, IL 60062
USA : 1-888-600-6441
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.SEND ME A FREE SAMPLE